124 related articles for article (PubMed ID: 28063163)
1. Immediate versus modified release hydrocortisone in mitotane-treated patients with adrenocortical cancer.
Weigel M; Hahner S; Sherlock M; Agha A; Behan LA; Stewart PM; Arlt W; Beier D; Frey K; Zopf K; Quinkler M
Clin Endocrinol (Oxf); 2017 Apr; 86(4):499-505. PubMed ID: 28063163
[TBL] [Abstract][Full Text] [Related]
2. Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study.
Alexandraki KI; Kaltsas GA; le Roux CW; Fassnacht M; Ajodha S; Christ-Crain M; Akker SA; Drake WM; Edwards R; Allolio B; Grossman AB
Clin Endocrinol (Oxf); 2010 Mar; 72(3):305-11. PubMed ID: 19473175
[TBL] [Abstract][Full Text] [Related]
3. Effects of mitotane on the hypothalamic-pituitary-adrenal axis in patients with adrenocortical carcinoma.
Reimondo G; Puglisi S; Zaggia B; Basile V; Saba L; Perotti P; De Francia S; Volante M; Zatelli MC; Cannavò S; Terzolo M
Eur J Endocrinol; 2017 Oct; 177(4):361-367. PubMed ID: 28780517
[TBL] [Abstract][Full Text] [Related]
4. Hair cortisol measurement in mitotane-treated adrenocortical cancer patients.
Manenschijn L; Quinkler M; van Rossum EF
Horm Metab Res; 2014 Apr; 46(4):299-304. PubMed ID: 24627099
[TBL] [Abstract][Full Text] [Related]
5. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement.
Chortis V; Taylor AE; Schneider P; Tomlinson JW; Hughes BA; O'Neil DM; Libé R; Allolio B; Bertagna X; Bertherat J; Beuschlein F; Fassnacht M; Karavitaki N; Mannelli M; Mantero F; Opocher G; Porfiri E; Quinkler M; Sherlock M; Terzolo M; Nightingale P; Shackleton CH; Stewart PM; Hahner S; Arlt W
J Clin Endocrinol Metab; 2013 Jan; 98(1):161-71. PubMed ID: 23162091
[TBL] [Abstract][Full Text] [Related]
6. The impact of mitotane therapy on serum-free proteins in patients with adrenocortical carcinoma.
Lech M; Ranasinghe R; Vincent RP; Taylor DR; Ghataore L; Luxton J; Lajeunesse-Trempe F; Roser P; Drakou EE; Chuah LL; Grossman AB; Aylwin SJB; Dimitriadis GK
Endocr Connect; 2024 Mar; 13(3):. PubMed ID: 38236710
[TBL] [Abstract][Full Text] [Related]
7. Assessment of salivary free cortisol levels by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in patients treated with mitotane.
Carrozza C; Lapolla R; Gervasoni J; Rota CA; Locantore P; Pontecorvi A; Zuppi C; Persichilli S
Hormones (Athens); 2012; 11(3):344-9. PubMed ID: 22908067
[TBL] [Abstract][Full Text] [Related]
8. Use of the urine cortisol-to-creatinine ratio for monitoring dogs with pituitary-dependent hyperadrenocorticism during induction treatment with mitotane (o,p'-DDD).
Randolph JF; Toomey J; Center SA; Scarlett JM; Reimers T; Graham P; Nachreiner RF
Am J Vet Res; 1998 Mar; 59(3):258-61. PubMed ID: 9522940
[TBL] [Abstract][Full Text] [Related]
9. Mitotane treatment of 32 dogs with cortisol-secreting adrenocortical neoplasms.
Kintzer PP; Peterson ME
J Am Vet Med Assoc; 1994 Jul; 205(1):54-61. PubMed ID: 7928549
[TBL] [Abstract][Full Text] [Related]
10. Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia.
Merza Z; Rostami-Hodjegan A; Memmott A; Doane A; Ibbotson V; Newell-Price J; Tucker GT; Ross RJ
Clin Endocrinol (Oxf); 2006 Jul; 65(1):45-50. PubMed ID: 16817818
[TBL] [Abstract][Full Text] [Related]
11. Rectal hydrocortisone during stress in patients with adrenal insufficiency.
De Vroede M; Beukering R; Spit M; Jansen M
Arch Dis Child; 1998 Jun; 78(6):544-7. PubMed ID: 9713011
[TBL] [Abstract][Full Text] [Related]
12. Changes in total and acylated ghrelin levels during mitotane treatment in patients with adrenocortical carcinoma.
Komarowska H; Ruciński M; Fichna M; Bromińska B; Iżycki D; Czarnywojtek A; Ruchała M
Pol Arch Intern Med; 2019 Aug; 129(7-8):469-475. PubMed ID: 31169262
[TBL] [Abstract][Full Text] [Related]
13. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly.
Daffara F; De Francia S; Reimondo G; Zaggia B; Aroasio E; Porpiglia F; Volante M; Termine A; Di Carlo F; Dogliotti L; Angeli A; Berruti A; Terzolo M
Endocr Relat Cancer; 2008 Dec; 15(4):1043-53. PubMed ID: 18824557
[TBL] [Abstract][Full Text] [Related]
14. Interferon-β is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane.
van Koetsveld PM; Vitale G; Feelders RA; Waaijers M; Sprij-Mooij DM; de Krijger RR; Speel EJ; Hofland J; Lamberts SW; de Herder WW; Hofland LJ
Endocr Relat Cancer; 2013 Jun; 20(3):443-54. PubMed ID: 23507702
[TBL] [Abstract][Full Text] [Related]
15. Treatment of adrenal cortical carcinoma with mitotane: outcome and complications.
Lim MC; Tan YO; Chong PY; Cheah JS
Ann Acad Med Singap; 1990 Jul; 19(4):540-4. PubMed ID: 2171414
[TBL] [Abstract][Full Text] [Related]
16. The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures.
van Koetsveld PM; Creemers SG; Dogan F; Franssen GJH; de Herder WW; Feelders RA; Hofland LJ
J Clin Endocrinol Metab; 2020 Feb; 105(2):407-17. PubMed ID: 31586196
[TBL] [Abstract][Full Text] [Related]
17. Elevated post-dexamethasone suppression cortisol concentrations correlate with hormonal alterations of the hypothalamo-pituitary adrenal axis in patients with adrenal incidentalomas.
Tsagarakis S; Roboti C; Kokkoris P; Vasiliou V; Alevizaki C; Thalassinos N
Clin Endocrinol (Oxf); 1998 Aug; 49(2):165-71. PubMed ID: 9828902
[TBL] [Abstract][Full Text] [Related]
18. Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer.
Berruti A; Fassnacht M; Haak H; Else T; Baudin E; Sperone P; Kroiss M; Kerkhofs T; Williams AR; Ardito A; Leboulleux S; Volante M; Deutschbein T; Feelders R; Ronchi C; Grisanti S; Gelderblom H; Porpiglia F; Papotti M; Hammer GD; Allolio B; Terzolo M
Eur Urol; 2014 Apr; 65(4):832-8. PubMed ID: 24268504
[TBL] [Abstract][Full Text] [Related]
19. Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study.
Johannsson G; Bergthorsdottir R; Nilsson AG; Lennernas H; Hedner T; Skrtic S
Eur J Endocrinol; 2009 Jul; 161(1):119-30. PubMed ID: 19383806
[TBL] [Abstract][Full Text] [Related]
20. Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug.
Reidy-Lagunes DL; Lung B; Untch BR; Raj N; Hrabovsky A; Kelly C; Gerst S; Katz S; Kampel L; Chou J; Gopalan A; Saltz LB
Oncologist; 2017 Sep; 22(9):1102-1106. PubMed ID: 28559412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
